|
|
 |
|
Viewing report
|
|
|
|
China Dermatosis Drug Market Report 2008
Draco Healthcare Consulting LLC, March 2009, Pages: 106
Dermatosis diseases are common diseases in China with high incidence and recurrence rates. The dermatosis disease rate is about 1.23%, meaning that there are about 160 million Chinese dermatosis patients. Dermatosis drugs are ranked as the No. 3 best selling drug category (by retail sales volume) in China. There are more than 600 dermatosis drugs for external use in the Chinese drug retail market. The market size of the Chinese dermatosis drug market in 2007 is about RMB 9.718 billion (USD 1.39 billion at 7:1 exchange rate), with a same period growth of 16.73%.
The No.1 Company in the Chinese dermatosis drug market has changed hands in the last three years. Chongqing Huabang was No.1 in 2005, Novartis took over in 2006 and Chongqing Huabang re-gained the title in 2007.
The multinational pharmaceutical companies (MNCs) and joint-ventures are dominating the Chinese dermatosis drug market. Eight of the top 10 pharmaceutical companies are either MNCs or JVs. Only two Chinese companies are among the top 10 in 2007. This report has systemically analyzed the Chinese dermatosis drug market. All market estimates of drug utilization in China are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages (20-60%) of all hospital beds in these regions.
Market shares from all major players (MNCs and Chinese pharmaceutical companies) and major dermatosis products are analyzed systemically based on data from the Chinese hospitals. The comprehensive hospital utilization data present a clear picture of the competition landscape of Chinese dermatosis drug market and the market potential for your company's product(s) that already marketed in China or for the products that you are planning to bring to the China market.
This China Dermatosis Drug Market Report has been a Must Have reference for decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies.
Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to you.
Product Mentioned:
- Terbinafine
- Mometasone
- Lecithin-iodum Complex
- Povidone Iodide
- Hydrocortisone Butyrate
- Halometasone
- Viaminate
- Econazole Nitrate
- Calcipotriol
- Mupirocin
- Miconazole Nitrate
- Tretinoin
- Bifonazole
- Acitretin
- Halometasone/Triclosan
- Heparan
- Tretinoin
- Etretinate
- Anerdian
- Lidocaine
Customers who bought this item also bought
China Executive Summary of the Chinese Hospital Drug Utilization Volume 2nd Edition 2009
Dermatology - Skin Infections or Dermatosis or Skin Itching Drug Pipeline Report
Skin Infections or Dermatosis or Skin Itching Therapy Area Pipeline Report
Dermatology - A Colour Guide 2nd Edition
Medical Review Criteria Guidelines for Managing Care, 8th edition. (2009 Update)
|
|
|
|
